For the past few years, compounded semaglutide and tirzepatide have been the workaround that let millions of Americans access GLP-1 therapy without paying brand-name prices — legal during the drug shortages that plagued Ozempic, Wegovy, and Zepbound through 2023 and 2024. The FDA is now moving to close that door for good at the large-scale compounding level. On April 30, 2026, the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, and the public comment window on that proposal closed several weeks ago. A final decision is now pending — and if it goes the way the FDA’s own language suggests, it will end large-batch outsourcing-facility compounding of these drugs for good.
What the 503B Bulks List Actually Controls
This is a narrower and more technical action than it sounds, so it’s worth being precise about what it does and doesn’t touch. Section 503B of the Federal Food, Drug, and Cosmetic Act governs “outsourcing facilities” — large compounding operations that produce drugs in bulk, often without a patient-specific prescription, and ship them to clinics and telehealth providers across state lines. Those facilities can only compound from bulk drug substances (not FDA-approved finished products) if the substance appears on the 503B bulks list, or if the drug is currently on the FDA’s official shortage list. With Ozempic, Wegovy, Mounjaro, and Zepbound now broadly available and off the shortage list, outsourcing facilities have been leaning on 503B bulk compounding as their remaining legal pathway to keep making these drugs at scale. The FDA’s proposal would shut that pathway too.
Critically, this does not touch Section 503A compounding — the traditional model where a local pharmacy compounds a specific prescription for an individual patient under state board of pharmacy oversight. A 503A pharmacist filling an individualized prescription for a patient with a documented clinical reason (a dosage strength or formulation not commercially available, for instance) operates under an entirely separate legal framework that the 503B bulks list has no authority over. The distinction matters enormously for anyone trying to understand what’s actually changing here: this is about large-scale, semi-mass-produced compounding, not the individualized compounding pharmacies have always been allowed to do.
Why the FDA Says There’s No Clinical Need
The FDA’s determination hinges on a specific legal standard: bulk compounding is only justified when there’s a demonstrated “clinical need” that FDA-approved products can’t meet — typically a shortage, a formulation gap, or a documented patient-specific reason a commercial product won’t work. With semaglutide, tirzepatide, and liraglutide now manufactured and distributed at scale by Novo Nordisk and Eli Lilly in multiple approved formulations and doses (including Wegovy HD’s new 7.2 mg option and Foundayo’s oral tablet), the FDA reviewed nominations to keep these substances on the bulks list and concluded the clinical-need bar wasn’t met.
FDA Commissioner Marty Makary framed the action as a matter of protecting the integrity of the approval process itself, saying the move reflects the agency’s responsibility “to protect patients and preserve the integrity of the drug approval process.” That’s the core argument compounders will have to overcome in their comments: the FDA’s position is that once brand-name and generic-adjacent supply is adequate, mass compounding stops being a shortage workaround and starts being an end-run around the approval system that vets drugs for safety and manufacturing quality in the first place.
Where Things Stand Right Now
The comment period, originally set to close June 29, 2026, was extended to July 30 to give compounding pharmacies, outsourcing facilities, and patient advocacy groups more time to weigh in. That window has now closed, and the FDA has not yet issued a final determination as of this writing. Based on the agency’s own public statements, a final rule excluding all three substances looks like the likely outcome, though the exact timing isn’t set. When it lands, outsourcing facilities currently producing compounded semaglutide, tirzepatide, or liraglutide at scale will need to wind that production down or shift to individualized 503A-style compounding under a documented clinical justification.
Frequently Asked Questions
Does this mean compounded semaglutide will disappear entirely?
No. It specifically targets 503B outsourcing-facility bulk compounding. Individualized 503A compounding for a specific patient with a documented clinical reason remains legally separate and isn’t directly affected by this rule.
Why was compounding allowed in the first place?
Ozempic, Wegovy, Mounjaro, and Zepbound were on the FDA’s official drug shortage list for extended periods between 2022 and 2024, which legally opened the door for compounding pharmacies and outsourcing facilities to produce versions of these drugs. Once a drug comes off the shortage list, that legal justification disappears — which is part of why this proposal is happening now.
What’s the difference between 503A and 503B again?
503A covers traditional compounding pharmacies filling individual, patient-specific prescriptions under state pharmacy board oversight. 503B covers larger “outsourcing facilities” that can produce compounded drugs in bulk, often without individual prescriptions, under a different and more industrial-scale regulatory framework. This proposal only affects the 503B pathway.
How does this connect to the recent RUO peptide warning letters?
They’re part of the same broader enforcement posture. While the warning letters target online sellers marketing unapproved peptides as “research use only,” this 503B action targets a different category — licensed compounding facilities operating in a regulatory gray zone that opened during the drug shortages. Read more in our coverage of the FDA’s 2026 warning letter wave.
The Bigger Picture
Compounded GLP-1s became a multi-billion-dollar shadow market almost by accident, born out of genuine supply shortages that left patients unable to get brand-name drugs. With those shortages resolved and multiple approved formulations now on the market — including lower-cost and higher-dose options from both major manufacturers — the FDA’s position is that the original justification no longer exists. If the exclusion becomes final, patients currently relying on compounded semaglutide or tirzepatide through an outsourcing facility should expect to transition to an FDA-approved product, and should talk to their prescriber well before any supply disruption happens.
This article is for educational purposes only and summarizes publicly available FDA regulatory documents. It is not legal or medical advice. If you currently use a compounded GLP-1 medication, talk to your prescriber about your options before any change in availability.